Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma
Blood Adv
.
2024 May 14:bloodadvances.2023011089.
doi: 10.1182/bloodadvances.2023011089.
Online ahead of print.
Authors
Giuseppe Gritti
1
,
Anton Belousov
2
,
James Relf
3
,
Mark Dixon
3
,
Maneesh Tandon
4
,
Krishna V Komanduri
5
Affiliations
1
Ospedale Papa Giovanni XXIII, Bergamo, Italy.
2
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
3
Roche Products Ltd, Welwyn Garden City, United Kingdom.
4
Roche Products Ltd, United Kingdom.
5
University of California, San Francisco, San Francisco, California, United States.
PMID:
38743882
DOI:
10.1182/bloodadvances.2023011089
No abstract available